Autolus cuts workforce 13%; expects $8M restructuring charge, $15M annualized savings

Autolus Therapeutics plc

Reduces workforce ~13% as part of operational efficiency plan; impacted employees receive severance and benefits.
Expects total restructuring charges of ~$8M, primarily severance, recognized in H1 2026; plan substantially complete by Q3 2026.
Reaffirms FY 2026 AUCATZYL net product revenue guidance of $120M-$135M, up from $74M in 2025.
Expects ~$15M annualized cost savings beginning in 2027; aims for positive gross margin in 2026.
Clinical programs on track: CATULUS (pediatric ALL), LUMINA (lupus nephritis), BOBCAT (MS).

item 2.05item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.